Nuvigil NDA On Schedule For First Quarter; Cephalon Touts Duration of Action
This article was originally published in Pharmaceutical Approvals Monthly
Cephalon on track to file its insomnia agent Nuvigil during the first quarter, firm says
You may also be interested in...
Cephalon goal of four NDA submissions in 14 months is on-track, with approvals forecast to double size of company by 2008. Pediatric sales force of 250 to be hired to detail modafinil for ADHD, with debut slated for early 2006. FDA rejects trade name Attenace. OraVescent breakthrough cancer pain NDA slated for Q3 2005; Gabitril sNDA for generalized anxiety in Q1 2006
Neurocrine to refile indiplon after meeting with FDA. Agency refuses to file application for the immediate-release formulation of Pfizer/Neurocrine’s insomnia agent due to difficulties with the electronic NDA. Firm also plans to reformat and refile its modified-release NDA to ensure consistency
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011